gemcitabine 40mg/ml concentrate for solution for infusion - (5ml vial)
fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents
gemcitabine 40mg/ml concentrate for solution for infusion - (25ml vial)
fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents
gemcitabine 40mg/ml concentrate for solution for infusion - (50ml vial)
fresenius kabi oncology plc lion court, farnham road, bordon, hampshire, gu35 0nf, united kingdom - gemcitabine hydrochloride - concentrate for solution for infusion - gemcitabine hydrochloride 40 mg - antineoplastic agents
gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial
fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine
gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial
fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine
gemcitabine fresenius kabi 40 mg/ml inf. sol. (conc.) i.v. vial
fresenius kabi sa-nv - gemcitabine hydrochloride - eq. gemcitabine 40 mg/ml - concentrate for solution for infusion - 40 mg/ml - gemcitabine hydrochloride - gemcitabine
gemcitabine 40mg/ml concentrate for solution for infusion
fresenius kabi oncology plc - gemcitabine hydrochloride - concentrate for solution for infusion - 40 milligram(s)/millilitre - pyrimidine analogues; gemcitabine
gemcitabine 40 mg/ml concentrate for solution for infusion
fresenius kabi deutschland gmbh - gemcitabine - concentrate for solution for infusion - 40 milligram(s)/millilitre - pyrimidine analogues; gemcitabine
gemcitabine kabi gemcitabine (as hydrochloride) 2000 mg/52.6 ml concentrated solution for injection vial
fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 2277.2 mg (equivalent: gemcitabine, qty 2000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.
gemcitabine kabi gemcitabine (as hydrochloride) 1000 mg/26.3 ml concentrated solution for injection vial
fresenius kabi australia pty ltd - gemcitabine hydrochloride, quantity: 1138.6 mg (equivalent: gemcitabine, qty 1000 mg) - injection, concentrated - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections - gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic non-small cell lung cancer. gemcitabine kabi is indicated for treatment of patients with locally advance or metastatic adenocarcinoma of the pancreas. gemcitabine is also indicated for patients with 5-fu refractory pancreatic cancer. gemcitabine kabi, alone or in combination with cisplatin, is indicated for treatment of patients with bladder cancer. gemcitabine kabi, in combination with paclitaxel, is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. gemcitabine kabi, in combinatin with carboplatin, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma, who have relapsed > 6 months following platinum-based therapy.